Yang Jian, Liu Ying, Liu Shi
Central Laboratory, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China.
Department of Medical Oncology, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China.
World J Gastrointest Oncol. 2023 Feb 15;15(2):368-371. doi: 10.4251/wjgo.v15.i2.368.
The coronavirus disease 2019 (COVID-19) pandemic has become a global burden, further exacerbating the occurrence of risk events in cancer patients. The high risk of death from pancreatic cancer makes it one of the most lethal malignancies. Recently, it was reported in the that COVID-19 influences pancreatic cancer progression the lung-gut-pancreatic axis, and the authors provided insights into the intrinsic crosstalk mechanisms in which the gut microbiota is involved, the characteristics and effects of inflammatory factors, and immunotherapeutic strategies for treating both diseases. Here, we review the latest cutting-edge researches in the field of the lung-gut-pancreatic axis and discuss future perspectives to address the severe survival challenges posed by the COVID-19 pandemic in patients with pancreatic cancer.
2019年冠状病毒病（COVID-19）大流行已成为全球负担，进一步加剧了癌症患者风险事件的发生。胰腺癌的高死亡风险使其成为最致命的恶性肿瘤之一。最近，有报道称COVID-19通过肺-肠-胰腺轴影响胰腺癌进展，作者深入探讨了肠道微生物群参与的内在相互作用机制、炎症因子的特征和作用以及治疗这两种疾病的免疫治疗策略。在此，我们综述肺-肠-胰腺轴领域的最新前沿研究，并探讨应对COVID-19大流行给胰腺癌患者带来的严峻生存挑战的未来前景。
